 Connection
Paul Prather to Humans
This is a "connection" page, showing publications Paul Prather has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.413 |
|
|
|
-
Shoeib AM, Benson LN, Mu S, MacMillan-Crow LA, Prather PL. Non-Canonical Cannabinoid Receptors with Distinct Binding and Signaling Properties in Prostate and Other Cancer Cell Types Mediate Cell Death. Int J Mol Sci. 2022 Mar 11; 23(6).
Score: 0.034
-
Shoeib AM, Yarbrough AL, Ford BM, Franks LN, Urbaniak A, Hensley LL, Benson LN, Mu S, Radominska-Pandya A, Prather PL. Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development. Life Sci. 2021 Nov 15; 285:119993.
Score: 0.033
-
Prather PL. Preface to DMR special edition 'Cannabinoid receptors and ligands: therapeutic drug development and abuse potential'. Drug Metab Rev. 2018 02; 50(1):1-2.
Score: 0.025
-
Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic Pot: Not Your Grandfather's Marijuana. Trends Pharmacol Sci. 2017 03; 38(3):257-276.
Score: 0.024
-
Ford BM, Franks LN, Radominska-Pandya A, Prather PL. Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development. PLoS One. 2016; 11(12):e0167240.
Score: 0.023
-
Franks LN, Ford BM, Madadi NR, Penthala NR, Crooks PA, Prather PL. Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs. Eur J Pharmacol. 2014 Aug 15; 737:140-8.
Score: 0.020
-
Prather PL, FrancisDevaraj F, Dates CR, Greer AK, Bratton SM, Ford BM, Franks LN, Radominska-Pandya A. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen. Biochem Biophys Res Commun. 2013 Nov 15; 441(2):339-43.
Score: 0.019
-
Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to ?(9)-THC: mechanism underlying greater toxicity? Life Sci. 2014 Feb 27; 97(1):45-54.
Score: 0.019
-
Brents LK, Prather PL. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev. 2014 Feb; 46(1):72-85.
Score: 0.019
-
Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol. 2013 Jun 01; 269(2):100-8.
Score: 0.018
-
Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies. Neuropharmacology. 2012 Oct; 63(5):905-15.
Score: 0.017
-
Seely KA, Brents LK, Radominska-Pandya A, Endres GW, Keyes GS, Moran JH, Prather PL. A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chem Res Toxicol. 2012 Apr 16; 25(4):825-7.
Score: 0.017
-
Seely KA, Levi MS, Prather PL. The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists. J Pharmacol Exp Ther. 2009 Jul; 330(1):31-9.
Score: 0.014
-
Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem. 2007 Apr; 101(1):87-98.
Score: 0.012
-
Shoemaker JL, Ruckle MB, Mayeux PR, Prather PL. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. J Pharmacol Exp Ther. 2005 Nov; 315(2):828-38.
Score: 0.011
-
Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, Prather PL. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. J Pharmacol Exp Ther. 2005 Aug; 314(2):868-75.
Score: 0.011
-
Fulo HF, Shoeib A, Cabanlong CV, Williams AH, Zhan CG, Prather PL, Dudley GB. Synthesis, Molecular Pharmacology, and Structure-Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists. J Med Chem. 2021 05 13; 64(9):6381-6396.
Score: 0.008
-
Pinson AO, Pouncey DL, Schleiff MA, Fantegrossi WE, Prather PL, Radominska-Pandya A, Boysen G, Miller GP. Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics. Molecules. 2020 Oct 20; 25(20).
Score: 0.008
-
Penthala NR, Shoeib A, Dachavaram SS, Cabanlong CV, Yang J, Zhan CG, Prather PL, Crooks PA. 7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands. Bioorg Med Chem Lett. 2020 11 15; 30(22):127501.
Score: 0.008
-
Pinson A, Yarbrough AL, Bush JM, Cabanlong CV, Shoeib A, Jackson BK, Fukuda S, Gogoi J, Fantegrossi WE, McCain K, Prather PL, Fujiwara R, Radominska-Pandya A. Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity. Pharmacol Biochem Behav. 2020 08; 195:172949.
Score: 0.007
-
Jones S, Yarbrough AL, Fantegrossi WE, Prather PL, Bush JM, Radominska-Pandya A, Fujiwara R. Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135). Pharmacol Res Perspect. 2020 02; 8(1):e00561.
Score: 0.007
-
Jones S, Yarbrough AL, Shoeib A, Bush JM, Fantegrossi WE, Prather PL, Radominska-Pandya A, Fujiwara R. Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22). Xenobiotica. 2019 Dec; 49(12):1388-1395.
Score: 0.007
-
Patton AL, Seely KA, Yarbrough AL, Fantegrossi W, James LP, McCain KR, Fujiwara R, Prather PL, Moran JH, Radominska-Pandya A. Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants. Biochem Biophys Res Commun. 2018 04 06; 498(3):597-602.
Score: 0.006
-
Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH. Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int. 2013 Dec 10; 233(1-3):416-22.
Score: 0.005
-
Vasiljevik T, Franks LN, Ford BM, Douglas JT, Prather PL, Fantegrossi WE, Prisinzano TE. Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse. J Med Chem. 2013 Jun 13; 56(11):4537-50.
Score: 0.005
-
Madadi NR, Penthala NR, Brents LK, Ford BM, Prather PL, Crooks PA. Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors. Bioorg Med Chem Lett. 2013 Apr 01; 23(7):2019-21.
Score: 0.004
-
Safe SH, Prather PL, Brents LK, Chadalapaka G, Jutooru I. Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs. Anticancer Agents Med Chem. 2012 Dec; 12(10):1211-20.
Score: 0.004
-
Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos. 2012 Nov; 40(11):2174-84.
Score: 0.004
-
Liu X, Jutooru I, Lei P, Kim K, Lee SO, Brents LK, Prather PL, Safe S. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer. Mol Cancer Ther. 2012 Jul; 11(7):1421-31.
Score: 0.004
-
Koryakina Y, Jones SM, Cornett LE, Seely K, Brents L, Prather PL, Kofman A, Kurten RC. Effects of the ?-agonist, isoprenaline, on the down-regulation, functional responsiveness and trafficking of ?2-adrenergic receptors with N-terminal polymorphisms. Cell Biol Int. 2012; 36(12):1171-83.
Score: 0.004
-
Brents LK, Medina-Bolivar F, Seely KA, Nair V, Bratton SM, Nopo-Olazabal L, Patel RY, Liu H, Doerksen RJ, Prather PL, Radominska-Pandya A. Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. Xenobiotica. 2012 Feb; 42(2):139-56.
Score: 0.004
-
Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, Prather PL, James LP, Radominska-Pandya A, Moran JH. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem. 2011 Jun 01; 83(11):4228-36.
Score: 0.004
-
Seely KA, Prather PL, James LP, Moran JH. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv. 2011 Feb; 11(1):36-51.
Score: 0.004
-
Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, Finel M, Miller GP, Radominska-Pandya A, Moran JH. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos. 2009 Jul; 37(7):1496-504.
Score: 0.003
-
McCormack K, Prather P, Chapleo C. Some new insights into the effects of opioids in phasic and tonic nociceptive tests. Pain. 1998 Nov; 78(2):79-98.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|